

**U.S. District Court
District of Delaware (Wilmington)
CIVIL DOCKET FOR CASE #: 1:24-cv-00882-RGA-SRF**

Genzyme Corporation v. Sarepta Therapeutics, Inc. et al
Assigned to: Judge Richard G. Andrews
Referred to: Judge Sherry R. Fallon

Date Filed: 07/26/2024
Jury Demand: Plaintiff
Nature of Suit: 830 Patent
Jurisdiction: Federal Question

Related Cases: 1:20-cv-01226-RGA

1:21-cv-01736-RGA

1:23-cv-00554-RGA

1:23-cv-00667-RGA

Cause: 35:1 Patent Infringement

Plaintiff

represented by **David E. Wilks**
Wilks Law, LLC
4250 Lancaster Pike
Suite 200
Wilmington, DE 19805
302-225-0858
Fax: 302-225-0851
Email: dwilks@wilks.law
LEAD ATTORNEY
ATTORNEY TO BE NOTICED

Donald C. Vavala , III
Wilks Law, LLC
4250 Lancaster Pike
Suite 200
Wilmington, DE 19805
302-225-0854
Fax: 302-225-0851
Email: cvavala@wilks.law
LEAD ATTORNEY
ATTORNEY TO BE NOTICED

Amanda K. Antons
Email: amanda.antons@dechert.com
PRO HAC VICE
ATTORNEY TO BE NOTICED

Jonathan D. Loeb
Email: jonathan.loeb@dechert.com
TERMINATED: 05/27/2025
PRO HAC VICE
ATTORNEY TO BE NOTICED

Judah Bellin
Email: Judah.Bellin@dechert.com
PRO HAC VICE
ATTORNEY TO BE NOTICED

Katherine A. Helm
Email: khelm@dechert.com
PRO HAC VICE
ATTORNEY TO BE NOTICED

Martin J. Black
Email: martin.black@dechert.com
PRO HAC VICE
ATTORNEY TO BE NOTICED

Noah M. Leibowitz
Email: noah.leibowitz@dechert.com
PRO HAC VICE
ATTORNEY TO BE NOTICED

Scott B. Czerwonka
Wilks Law, LLC
4250 Lancaster Pike
Ste 200
Wilmington, DE 19805
302-230-5154
Fax: 302-225-0851
Email: sczerwonka@wilks.law
ATTORNEY TO BE NOTICED

Sharon K. Gagliardi
Email: sharon.gagliardi@dechert.com
PRO HAC VICE
ATTORNEY TO BE NOTICED

Shyam Shanker
Email: shyam.shanker@dechert.com

*PRO HAC VICE
ATTORNEY TO BE NOTICED*

V.

Defendant

Sarepta Therapeutics, Inc.

represented by **Alexandra Kim**
Email: alexandrakim@quinnemanuel.com
*PRO HAC VICE
ATTORNEY TO BE NOTICED*

Derek James Fahnestock
Morris, Nichols, Arsht & Tunnell LLP
1201 North Market Street
P.O. Box 1347
Wilmington, DE 19899
302-658-9200
Email: dfahnestock@mnat.com
ATTORNEY TO BE NOTICED

John D. Livingstone
Email: john.livingstone@finnegan.com
*PRO HAC VICE
ATTORNEY TO BE NOTICED*

M. David Weingarten
Email: M.David.weingarten@finnegan.com
*PRO HAC VICE
ATTORNEY TO BE NOTICED*

M. David Weingarten , Ph.D
Email: david.weingarten@finnegan.com
*PRO HAC VICE
ATTORNEY TO BE NOTICED*

Megan Elizabeth Dellinger
Morris, Nichols, Arsht & Tunnell LLP
1201 North Market Street
P.O. Box 1347
Wilmington, DE 19899
302-351-9366
Email: mdellinger@mnat.com
ATTORNEY TO BE NOTICED

Yihan Liu
Email: valentinaliu@quinnemanuel.com
*PRO HAC VICE
ATTORNEY TO BE NOTICED*

Defendant

represented by **Alexandra Kim**
 (See above for address)
PRO HAC VICE
ATTORNEY TO BE NOTICED

Derek James Fahnstock
 (See above for address)
ATTORNEY TO BE NOTICED

John D. Livingstone
 (See above for address)
PRO HAC VICE
ATTORNEY TO BE NOTICED

M. David Weingarten
 (See above for address)
PRO HAC VICE
ATTORNEY TO BE NOTICED

M. David Weingarten , Ph.D
 (See above for address)
PRO HAC VICE
ATTORNEY TO BE NOTICED

Megan Elizabeth Dellinger
 (See above for address)
ATTORNEY TO BE NOTICED

Yihan Liu
 (See above for address)
PRO HAC VICE
ATTORNEY TO BE NOTICED

#	Docket Text	Date Filed
1	COMPLAINT with Jury Demand against Sarepta Therapeutics Three, LLC, Sarepta Therapeutics, Inc. (Filing fee \$ 405, receipt number ADEDC-4462061) - filed by Genzyme Corporation. (Attachments: # 1 Exhibits A-D, # 2 Exhibits E-H, # 3 Civil Cover Sheet) (oam) Modified on 7/31/2024 (nms). (Entered: 07/29/2024)	07/26/2024
2	Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (oam) (Entered: 07/29/2024)	07/26/2024
3	Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Aventis Inc., Other Affiliate Sanofi for Genzyme Corporation filed by Genzyme Corporation. (oam) (Entered: 07/29/2024)	07/26/2024
	No Summons Issued. (oam) (Entered: 07/29/2024)	07/26/2024
4	Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 9,051,542; 7,704,721 . (Czerwotka, Scott) (Entered: 07/29/2024)	07/29/2024
	Case Assigned to Judge Richard G. Andrews. Please include the initials of the Judge (RGA) after the case number on all documents filed. (rjb) (Entered: 07/31/2024)	07/31/2024
5	Pro Hac Vice Fee - Credit Card Payment received for Sharon K. Gagliardi, Jonathan D.J. Loeb, Katherine A. Helm, Martin J. Black, and Amanda K. Antons. (Payment of \$ 250, receipt number ADEDC-4466711).(Wilks, David) (Entered: 08/02/2024)	08/02/2024
6	MOTION for Pro Hac Vice Appearance of Attorney Sharon K. Gagliardi - filed by Genzyme Corporation. (Czerwotka, Scott) (Entered: 08/02/2024)	08/02/2024
7	MOTION for Pro Hac Vice Appearance of Attorney Jonathan D.J. Loeb - filed by Genzyme Corporation. (Czerwotka, Scott) (Entered: 08/02/2024)	08/02/2024
8	MOTION for Pro Hac Vice Appearance of Attorney Katherine A. Helm - filed by Genzyme Corporation. (Czerwotka, Scott) (Entered: 08/02/2024)	08/02/2024
9	MOTION for Pro Hac Vice Appearance of Attorney Martin J. Black - filed by Genzyme Corporation. (Czerwotka, Scott) (Entered: 08/02/2024)	08/02/2024
10	MOTION for Pro Hac Vice Appearance of Attorney Amanda K. Antons - filed by Genzyme Corporation. (Czerwotka, Scott) (Entered: 08/02/2024)	08/02/2024

#	Docket Text	Date Filed
11	Pro Hac Vice Fee - Credit Card Payment received for Noah M. Leibowitz. (Payment of \$ 50, receipt number ADEDC-4466842). (Wilks, David) (Entered: 08/02/2024)	08/02/2024
12	MOTION for Pro Hac Vice Appearance of Attorney Noah M. Leibowitz - filed by Genzyme Corporation. (Czerwonka, Scott) (Entered: 08/02/2024)	08/02/2024
	SO ORDERED, re 7 MOTION for Pro Hac Vice Appearance of Attorney Jonathan D.J. Loeb, filed by Genzyme Corporation, 6 MOTION for Pro Hac Vice Appearance of Attorney Sharon K. Gagliardi, filed by Genzyme Corporation, 8 MOTION for Pro Hac Vice Appearance of Attorney Katherine A. Helm filed by Genzyme Corporation, 10 MOTION for Pro Hac Vice Appearance of Attorney Amanda K. Antons, filed by Genzyme Corporation, 9 MOTION for Pro Hac Vice Appearance of Attorney Martin J. Black, filed by Genzyme Corporation, and 12 MOTION for Pro Hac Vice Appearance of Attorney Noah M. Leibowitz, filed by Genzyme Corporation. Signed by Judge Richard G. Andrews on 8/2/2024. (nms) (Entered: 08/02/2024)	08/02/2024
	Pro Hac Vice Attorney Jonathan D.J. Loeb, Noah M. Leibowitz, Amanda K. Antons, Sharon K. Gagliardi, Katherine A. Helm for Genzyme Corporation added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (mws) (Entered: 08/02/2024)	08/02/2024
13	SUMMONS Returned Executed by Genzyme Corporation.Sarepta Therapeutics, Inc. served on 10/10/2024, answer due 10/31/2024. (Wilks, David) (Entered: 10/11/2024)	10/11/2024
14	SUMMONS Returned Executed by Genzyme Corporation.Sarepta Therapeutics Three, LLC served on 10/10/2024, answer due 10/31/2024. (Wilks, David) (Entered: 10/11/2024)	10/11/2024
	Pro Hac Vice Attorney Martin J. Black for Genzyme Corporation added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (scs) (Entered: 10/15/2024)	10/14/2024
15	MOTION for Pro Hac Vice Appearance of Attorney Andrew M. Berdon, Robert B. Wilson, Anne S. Toker, and Anastasia M. Fernands - filed by Sarepta Therapeutics Three, LLC, Sarepta Therapeutics, Inc.. (Dellinger, Megan) (Entered: 10/23/2024)	10/23/2024
16	Pro Hac Vice Fee - Credit Card Payment received for Andrew M. Berdon, Robert B. Wilson, Anne S. Toker, and Anastasia M. Fernands. (re 15 MOTION for Pro Hac Vice Appearance of Attorney Andrew M. Berdon, Robert B. Wilson, Anne S. Toker, and Anastasia M. Fernands)(Payment of \$ 200, receipt number ADEDC-4530908).(Dellinger, Megan) (Entered: 10/23/2024)	10/23/2024
	SO ORDERED, re 15 MOTION for Pro Hac Vice Appearance of Attorney Andrew M. Berdon, Robert B. Wilson, Anne S. Toker, and Anastasia M. Fernands, filed by Sarepta Therapeutics Three, LLC, Sarepta Therapeutics, Inc.. Signed by Judge Richard G. Andrews on 10/24/2024. (nms) (Entered: 10/24/2024)	10/24/2024
17	MOTION for Pro Hac Vice Appearance of Attorney John D. Livingstone and M. David Weingarten - filed by Sarepta Therapeutics Three, LLC, Sarepta Therapeutics, Inc.. (Fahnestock, Derek) (Entered: 10/25/2024)	10/25/2024
18	Pro Hac Vice Fee - Credit Card Payment received for John D. Livingstone and M. David Weingarten. (re 17 MOTION for Pro Hac Vice Appearance of Attorney John D. Livingstone and M. David Weingarten)(Payment of \$ 100, receipt number ADEDC-4532493).(Fahnestock, Derek) (Entered: 10/25/2024)	10/25/2024
	SO ORDERED, re 17 MOTION for Pro Hac Vice Appearance of Attorney John D. Livingstone and M. David Weingarten, filed by Sarepta Therapeutics Three, LLC, Sarepta Therapeutics, Inc.. Signed by Judge Richard G. Andrews on 10/25/2024. (nms) (Entered: 10/25/2024)	10/25/2024
	Pro Hac Vice Attorney M. David Weingarten, PhD,John D. Livingstone for Sarepta Therapeutics Three, LLC, Sarepta Therapeutics, Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (scs) (Entered: 10/28/2024)	10/28/2024
	Pro Hac Vice Attorney John D. Livingstone and M. David Weingarten for Sarepta Therapeutics Three, LLC and Sarepta Therapeutics, Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (cdd) (Entered: 10/28/2024)	10/28/2024
19	PARTIAL Motion to Dismiss - filed by Sarepta Therapeutics Three, LLC, Sarepta Therapeutics, Inc.. (Dellinger, Megan) Modified on 10/31/2024 (nms). (Entered: 10/31/2024)	10/31/2024
20	OPENING BRIEF in Support re 19 Partial Motion to Dismiss, filed by Sarepta Therapeutics Three, LLC, Sarepta Therapeutics, Inc.. Answering Brief/Response due date per Local Rules is 11/14/2024. (Dellinger, Megan) Modified on 10/31/2024 (nms). (Entered: 10/31/2024)	10/31/2024
21	Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Sarepta Therapeutics, Inc. for Sarepta Therapeutics Three, LLC filed by Sarepta Therapeutics Three, LLC, Sarepta Therapeutics, Inc.. (Dellinger, Megan) (Entered: 10/31/2024)	10/31/2024
22	STIPULATION and [Proposed] Order for Extension of Time by Genzyme Corporation. (Wilks, David) (Entered: 11/13/2024)	11/13/2024
	SO ORDERED, re 22 Stipulation and Proposed Order to Extend Time (*Reset Briefing Schedule: re 19 Partial Motion to Dismiss. Answering Brief due 11/21/2024, Reply Brief due 12/9/2024). Signed by Judge Richard G. Andrews on 11/13/2024. (nms) (Entered: 11/13/2024)	11/13/2024

#	Docket Text	Date Filed
23	FIRST Amended Complaint against Sarepta Therapeutics Three, LLC, Sarepta Therapeutics, Inc.- filed by Genzyme Corporation. (Attachments: # 1 Exhibits A-E, # 2 Exhibits F-J)(Wilks, David) Modified on 11/21/2024 (nms). (Entered: 11/21/2024)	11/21/2024
24	STIPULATION and Proposed Order to Extend Time - filed by Sarepta Therapeutics, Inc., Sarepta Therapeutics Three, LLC. (Dellinger, Megan) Modified on 11/25/2024 (nms). (Entered: 11/25/2024)	11/25/2024
	SO ORDERED, re 24 STIPULATION and Proposed Order to Extend Time (*Reset Answer Deadlines: Sarepta Therapeutics Three, LLC answer due 12/12/2024; Sarepta Therapeutics, Inc. answer due 12/12/2024). Signed by Judge Richard G. Andrews on 11/25/2024. (nms) (Entered: 11/25/2024)	11/25/2024
25	NOTICE of Change of Address for Andrew M. Berdon, Robert B. Wilson, Anne S. Toker and Anastasia M. Fernands by Sarepta Therapeutics, Inc., Sarepta Therapeutics Three, LLC (Dellinger, Megan) (Entered: 12/09/2024)	12/09/2024
26	ANSWER to 23 Amended Complaint with Jury Demand, by Sarepta Therapeutics, Inc., Sarepta Therapeutics Three, LLC. (Attachments: # 1 Exhibits 1-4)(Dellinger, Megan) Modified on 12/12/2024 (nms). (Entered: 12/12/2024)	12/12/2024
27	Order Setting Rule 16(b) Conference: A Scheduling Conference is set for 1/15/2025, at 2:00 PM in Courtroom 6A (see Order for further details). Signed by Judge Richard G. Andrews on 12/18/2024. (nms) (Entered: 12/18/2024)	12/18/2024
28	NOTICE OF SERVICE of Plaintiffs First Set of Requests for Production of Documents and Things filed by Genzyme Corporation. (Wilks, David) (Entered: 01/09/2025)	01/09/2025
29	PROPOSED Scheduling Order, by Genzyme Corporation. (Czerwonka, Scott) Modified on 1/14/2025 (nms). (Entered: 01/13/2025)	01/13/2025
30	PROPOSED Order Regarding Production of Settlement and License Agreements, by Genzyme Corporation. (Wilks, David) Modified on 1/14/2025 (nms). (Entered: 01/14/2025)	01/14/2025
31	JOINT SCHEDULING ORDER: Joinder of Parties due by 8/1/2025. Amended Pleadings due by 8/1/2025. Fact Discovery completed by 2/20/2026. Dispositive Motions due by 8/14/2026. Answering Brief due 9/11/2026. Reply Brief due 10/2/2026. Joint Claim Construction Brief due by 10/3/2025. A Markman Hearing is set for 11/4/2025, at 9:00 AM in Courtroom 6A. A Pretrial Conference is set for 1/15/2027, at 9:00 AM in Courtroom 6A. A 5-day Jury Trial is set to start 1/25/2027, at 9:30 AM in Courtroom 6A (see Order for further details). Signed by Judge Richard G. Andrews on 1/14/2025. (nms) (Entered: 01/14/2025)	01/14/2025
32	ORAL ORDER: The Rule 16(b) Conference scheduled for 1/15/2024, is CANCELED. Ordered by Judge Richard G. Andrews on 1/14/2025. (nms) (Entered: 01/14/2025)	01/14/2025
33	ORDER Regarding Production of Settlement and License Agreements. Signed by Judge Richard G. Andrews on 1/15/2025. (nms) (Entered: 01/15/2025)	01/15/2025
34	NOTICE of Change of Address for Amanda K. Anton by Genzyme Corporation (Wilks, David) (Entered: 01/15/2025)	01/15/2025
	CORRECTING ENTRY: The letter filed at D.I. 35 on 1/15/2025, has been removed from the docket per counsel's request. The letter was filed in the wrong civil action. (nms) (Entered: 01/15/2025)	01/15/2025
35	NOTICE OF SERVICE of (1)First Set of Requests for Production of Documents and Things to Plaintiff Genzyme Corporation (Nos. 1-10); and (2) Initial Disclosures Pursuant to Fed. R. Civ. P. 26(a)(1) filed by Sarepta Therapeutics, Inc., Sarepta Therapeutics Three, LLC.(Fahnestock, Derek) (Entered: 01/21/2025)	01/21/2025
36	NOTICE OF SERVICE of Plaintiff's Rule 26(A)(1) Initial Disclosures filed by Genzyme Corporation.(Czerwonka, Scott) (Entered: 01/21/2025)	01/21/2025
37	NOTICE OF SERVICE of Plaintiff's Second Set of Requests for Production of Documents and Things (Nos. 9-151) filed by Genzyme Corporation.(Wilks, David) (Entered: 01/24/2025)	01/24/2025
38	NOTICE OF SERVICE of Sarepta Therapeutics, Inc. and Sarepta Therapeutics Three LLC's Objections and Responses to Plaintiff Genzyme Corporations First Set of Requests for Production of Documents and Things (Nos. 1-8) - filed by Sarepta Therapeutics, Inc., Sarepta Therapeutics Three, LLC.(Fahnestock, Derek) (Entered: 02/10/2025)	02/10/2025
39	STIPULATION and [Proposed] Order to Extend Time for the Parties to submit an Application for Protective Order by Genzyme Corporation. (Wilks, David) (Entered: 02/12/2025)	02/12/2025
	SO ORDERED, re 39 Stipulation and Proposed Order to Extend Time to submit proposed Protective Order to February 21, 2025. Signed by Judge Richard G. Andrews on 2/12/2025. (nms) (Entered: 02/12/2025)	02/12/2025
40	NOTICE OF SERVICE of Sarepta Therapeutics, Inc. and Sarepta Therapeutics Three LLC's Disclosures Pursuant to Paragraph 3 of the Default Standard for Discovery, Including Discovery of Electronically Stored Information - filed by Sarepta Therapeutics Three, LLC, Sarepta Therapeutics, Inc..(Fahnestock, Derek) (Entered: 02/14/2025)	02/14/2025
41	NOTICE OF SERVICE of (1) Plaintiffs Paragraph 3 Disclosures under the Default Standard for Discovery; and (2) Plaintiffs Disclosures under Paragraph 4(a) of the Default Standard for Discovery filed by Genzyme Corporation.(Wilks, David) (Entered: 02/14/2025)	02/14/2025

#	Docket Text	Date Filed
42	STIPULATION and [Proposed] Order to Extend Time to submit an application for protective order, by Genzyme Corporation. (Wilks, David) Modified on 2/20/2025 (nms). (Entered: 02/20/2025)	02/20/2025
43	NOTICE OF SERVICE of Genzyme Corporations Response to Sarepta Therapeutics, Inc. and Sarepta Therapeutics Three LLCs First Set of Requests for Production of Documents and Things (Nos. 1-10) filed by Genzyme Corporation.(Czerwonka, Scott) (Entered: 02/20/2025)	02/20/2025
	SO ORDERED, re 42 Stipulation and Proposed Order to Extend Time to submit an application for protective order by 2/28/2025. Signed by Judge Richard G. Andrews on 2/20/2025. (nms) (Entered: 02/20/2025)	02/20/2025
44	STIPULATION and Proposed Order to Extend Time to submit a proposed protective order to March 14, 2025 - filed by Sarepta Therapeutics Three, LLC, Sarepta Therapeutics, Inc.. (Fahnestock, Derek) Modified on 2/28/2025 (nms). (Entered: 02/28/2025)	02/28/2025
	SO ORDERED, re 44 STIPULATION and Proposed Order to Extend Time to submit a proposed protective order to March 14, 2025. Signed by Judge Richard G. Andrews on 2/28/2025. (nms) (Entered: 02/28/2025)	02/28/2025
45	NOTICE OF SERVICE of (1) Plaintiffs First Set of Interrogatories directed to Defendants; and (2) Plaintiffs Third Set of Requests for Production of Documents and Things filed by Genzyme Corporation.(Wilks, David) (Entered: 03/05/2025)	03/05/2025
46	NOTICE OF SERVICE of Sarepta Therapeutics, Inc. and Sarepta Therapeutics Three LLC's Objections and Responses to Plaintiff Genzyme Corporation's Second Set of Requests for Production of Documents and Things (Nos. 9-151) - filed by Sarepta Therapeutics Three, LLC, Sarepta Therapeutics, Inc..(Fahnestock, Derek) (Entered: 03/12/2025)	03/12/2025
47	STIPULATION and Proposed Order to Extend Time to Provide Documents by April 7, 2025 - filed by Sarepta Therapeutics Three, LLC, Sarepta Therapeutics, Inc.. (Fahnestock, Derek) Modified on 3/13/2025 (nms). (Entered: 03/13/2025)	03/13/2025
	SO ORDERED, re 47 STIPULATION and Proposed Order to Extend Time to Provide Documents. Signed by Judge Richard G. Andrews on 3/13/2025. (nms) (Entered: 03/13/2025)	03/13/2025
48	Proposed Stipulated Discovery Order, by Genzyme Corporation. (Attachments: # 1 Schedule A)(Wilks, David) Modified on 3/26/2025 (nms). (Entered: 03/26/2025)	03/26/2025
49	NOTICE of Appearance by Donald C. Vavala, III on behalf of Genzyme Corporation (Vavala, Donald) (Entered: 03/26/2025)	03/26/2025
50	SO ORDERED Granting 48 Stipulated Discovery Order. Signed by Judge Richard G. Andrews on 3/26/2025. (nms) (Entered: 03/26/2025)	03/26/2025
51	Letter to The Honorable Richard G. Andrews, from Megan E. Dellinger, regarding protective order dispute. (Attachments: # 1 Exhibits 1-15)(Dellinger, Megan) Modified on 3/31/2025 (nms). (Entered: 03/28/2025)	03/28/2025
52	Letter to the Honorable Richard G. Andrews, from David E. Wilks, regarding protective order dispute. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4)(Wilks, David) Modified on 3/31/2025 (nms). (Entered: 03/28/2025)	03/28/2025
53	ORAL ORDER: The parties have advised of an impasse regarding the agreement on a protective order (see D.I. 51 and D.I. 52). This disputed is now REFERRED to Magistrate Judge Sherry R. Fallon. Ordered by Judge Richard G. Andrews on 3/31/2025. (nms) (Entered: 03/31/2025)	03/31/2025
	REQUEST: Per Magistrate Judge Fallon's Standing Order Regarding Courtesy Copies, which requires two (2) courtesy copies of all briefs and two (2) copies of any other document filed in support of any briefs (i.e., appendices, exhibits, declarations, affidavits etc.), please submit to the Clerk's Office two copies of D.I. # 51 and 52 in an envelope addressed to Judge Fallon's chambers. (lih) (Entered: 03/31/2025)	03/31/2025
54	ORAL ORDER- re 51 Letter and 52 Letter. IT IS HEREBY ORDERED that the parties are instructed to file a "Motion for Teleconference to Resolve [Protective Order or Discovery] Dispute" by no later than April 2, 2025 pursuant to the court's discovery dispute procedures set forth in the Order regarding discovery matters available at www.ded.uscourts.gov/judge/magistrate-judge-sherry-r-fallon . Ordered by Judge Sherry R. Fallon on 4/1/2025. (lih) (Entered: 04/01/2025)	04/01/2025
55	Joint Motion for Teleconference to Resolve Protective Order Dispute - filed by Sarepta Therapeutics Three, LLC, Sarepta Therapeutics, Inc.. Motions referred to Sherry R. Fallon.(Fahnestock, Derek) Modified on 4/2/2025 (lih). (Entered: 04/02/2025)	04/02/2025
56	ORAL ORDER- re 51 Letter, 52 Letter, and 55 Joint MOTION for Teleconference to Resolve Protective Order Dispute. IT IS HEREBY ORDERED that the court shall resolve the protective order dispute based upon the letter briefing submitted to date without further briefing absent leave of court, and a discovery dispute teleconference will be scheduled at the court's convenience if the court determines it would be helpful. Ordered by Judge Sherry R. Fallon on 4/2/2025. (lih) (Entered: 04/02/2025)	04/02/2025
57	NOTICE OF SERVICE of (1) Sarepta Therapeutics, Inc. and Sarepta Therapeutics Three LLC's Objections and Responses to Plaintiff Genzyme Corporation's Third Set of Requests for Production of Documents and Things (Nos. 152-157) and (2) Sarepta Therapeutics, Inc. and Sarepta Therapeutics Three LLC's Objections and Responses to Plaintiff Genzyme Corporation's First Set of Interrogatories (Nos. 1-10) - filed by Sarepta Therapeutics Three, LLC, Sarepta Therapeutics, Inc..(Fahnestock, Derek) (Entered: 04/04/2025)	04/04/2025

#	Docket Text	Date Filed
58	ORAL ORDER re 55 Joint Motion for Teleconference to Resolve Protective Order Dispute. Having reviewed the parties' letter submissions regarding the protective order dispute, (D.I. 51; D.I. 52), IT IS ORDERED that Defendants' proposed protective order denying Plaintiff's in-house counsel access to Highly Confidential Information ("HCI"), (D.I. 51, Ex. 1), and Plaintiff's competing proposed protective order permitting access to HCI by its in-house counsel, (D.I. 52, Ex. 1), are ADOPTED-IN-PART. Defendants contend that Plaintiff's in-house counsel, Stephanie Donahue and Dr. Amanda Hoffman, should not be given access to HCI regarding Defendants' manufacturing processes for recombinant adeno-associated virus ("rAAV") gene therapies contained in Defendants' Biologics License Application ("BLA") and associated FDA correspondence due to the risk of inadvertent disclosure. (D.I. 51) Applying the framework set forth in In re Deutsche Bank Trust Co. Ams., 605 F.3d 1373, 1378 (Fed. Cir. 2010), which provides that limits on in-house counsel access to confidential information depend on whether counsel is involved in competitive decision-making, the court concludes that Donahue and Dr. Hoffman are not competitive decision-makers. Instead, their roles are limited to supervising and managing litigation against Defendants. (D.I. 51, Exs. 9-10; D.I. 52, Ex. 3 at ¶¶ 7-17, Ex. 4 at ¶¶ 8-18); Cf. PhishMe, Inc. v. Wombat Sec. Techs., Inc., C.A. No. 16-403-LPS-CJB, 2017 WL 4138961 (D. Del. Sept. 8, 2017) (concluding that general counsel was a competitive decision-maker where he was the only attorney providing legal advice to final decision-makers on issues such as pricing, product design, patent prosecution, and licensing). The risk of inadvertent disclosure is generally outweighed by in-house counsel's need for access to materials at issue in the litigation when in-house counsel's responsibilities are limited to litigation, with no competitive decision-making. See, e.g., British Telecomm's PLC v. IAC/InterActiveCorp, C.A. No. 18-366-WCB, 330 F.R.D. 387, 394 (D. Del. Mar. 18, 2019) (citing cases). Plaintiff's proposal further mitigates the risk of inadvertent disclosure by subjecting Donahue and Dr. Hoffman to a prosecution bar and bars on their involvement in citizen's petitions and competitive decision-making. (D.I. 52, Ex. 1 at ¶ 11(a)-(c); Ex. 3 at ¶¶ 22-27; Ex. 4 at ¶¶ 23-28) However, Defendants have shown that disclosure of the entire BLA to two in-house counsel may pose an unacceptable risk of inadvertent disclosure, citing another case brought by the same Plaintiff alleging infringement of one of the same patents, U.S. Patent No. 9,051,542. See Genzyme Corp. v. Novartis Gene Therapies, Inc., C.A. No. 21-1736-RGA, D.I. 89; D.I. 92 (D. Del. Dec. 1, 2022). The Novartis defendants similarly argued that details of the manufacturing processes for rAAV gene therapies were highly proprietary and irrelevant to the asserted patents. (D.I. 51, Ex. 7 at 1) The court determined that two specific subsections of the BLA (as opposed to the entire document Defendants seek to designate here) should be produced on an Outside Counsel Eyes Only basis. (D.I. 51, Ex. 5) To balance the parties' interests in a manner consistent with Novartis, IT IS ORDERED that: (A) Plaintiff may designate Donahue and Dr. Hoffman to review HCI consistent with the proposal at paragraph 16(a) of Plaintiff's proposed protective order, (D.I. 52, Ex. 1 at 12); (B) Defendants may include an "HCI Outside Counsel Only" designation which is narrower in scope than "all BLA submissions," (D.I. 51, Ex. 1 at 4); and (C) The proposed protective order shall include a mechanism for Plaintiff to request in-house counsel access for material designated "HCI Outside Counsel Only" on a case-by-case basis upon a showing that specific materials are necessary for in-house counsel to make decisions concerning this litigation. IT IS FURTHER ORDERED that a revised proposed protective order consistent with this Oral Order shall be due on or before April 25, 2025. Ordered by Judge Sherry R. Fallon on 4/11/2025. (lih) (Entered: 04/11/2025)	04/11/2025
59	NOTICE OF SERVICE of Plaintiffs Initial Claim Charts on Infringement pursuant to Paragraph 4(c) of the Default Standard for Discovery filed by Genzyme Corporation.(Wilks, David) (Entered: 04/16/2025)	04/16/2025
60	STIPULATION and Proposed Order to Extend Time to Submit Revised Proposed Protective Order to April 28, 2025 - filed by Sarepta Therapeutics Three, LLC, Sarepta Therapeutics, Inc.. (Fahnestock, Derek) Modified on 4/25/2025 (nms). (Entered: 04/25/2025)	04/25/2025
	SO ORDERED, re 60 STIPULATION TO EXTEND TIME for the parties to submit a revised proposed protective order to April 28, 2025. Signed by Judge Sherry R. Fallon on 4/25/2025. (Polito, Rebecca) (Entered: 04/25/2025)	04/25/2025
61	PROPOSED Protective Order, by Genzyme Corporation. (Attachments: # 1 Exhibit A)(Vavala, Donald) Modified on 4/29/2025 (nms). (Entered: 04/28/2025)	04/28/2025
62	Letter to the Honorable Sherry R. Fallon, from D. Charles Vavala, regarding revised Proposed Protective Order. (Vavala, Donald) Modified on 4/29/2025 (nms). (Entered: 04/28/2025)	04/28/2025
63	ORAL ORDER- re 61 Proposed Protective Order. The court's Oral Order of April 11, 2025 (D.I. 58) ordered the parties to submit a proposed protective order consistent with the court's rulings, nonetheless, the parties continue to dispute the extent to which Plaintiff's two in-house counsel may have access to "Highly Confidential Outside Counsel Only" ("HCI") information at paragraph 18.g(i) of the proposed protective order. The court finds that the language proposed by the Plaintiff is not consistent with the court's prior Order, therefore, paragraph 18.g.(i) is stricken and any disputes as to an in-house counsel's access to HCI shall be addressed pursuant to the mechanism in 18.g.(ii). IT IS FURTHER ORDERED that a revised proposed protective order consistent with this Oral Order shall be due on or before May 2, 2025. Ordered by Judge Sherry R. Fallon on 4/29/2025. (lih) (Entered: 04/29/2025)	04/29/2025
64	Revised Proposed Protective Order, by Genzyme Corporation. (Attachments: # 1 Exhibit A)(Vavala, Donald) Modified on 5/2/2025 (nms). (Entered: 05/02/2025)	05/02/2025
65	PROTECTIVE ORDER. Signed by Judge Sherry R. Fallon on 5/2/2025. (lih) (Entered: 05/02/2025)	05/02/2025
66	NOTICE of Change of Address by Donald C. Vavala, III (Vavala, Donald) (Entered: 05/06/2025)	05/06/2025
67	NOTICE OF SERVICE of (1) Sarepta Therapeutics, Inc. and Sarepta Therapeutics Three LLC's Second Set of Requests for Production of Documents and Things to Plaintiff Genzyme Corporation (Nos. 11-82) and (2) Sarepta Therapeutics, Inc. and Sarepta Therapeutics Three LLC's First Set of Interrogatories to Plaintiff Genzyme Corporation (Nos. 1-10) - filed by Sarepta Therapeutics Three, LLC, Sarepta Therapeutics, Inc..(Fahnestock, Derek) (Entered: 05/13/2025)	05/13/2025

#	Docket Text	Date Filed
68	NOTICE OF SERVICE of Sarepta Therapeutics, Inc. and Sarepta Therapeutics Three LLC's Initial Invalidity Contentions - filed by Sarepta Therapeutics Three, LLC, Sarepta Therapeutics, Inc..(Fahnestock, Derek) (Entered: 05/16/2025)	05/16/2025
69	NOTICE of Withdrawal of Counsel by Sarepta Therapeutics Three, LLC, Sarepta Therapeutics, Inc. (Dellinger, Megan) (Entered: 05/22/2025)	05/22/2025
70	Unopposed Motion for Leave to File Second Amended Complaint - filed by Genzyme Corporation. (Attachments: # 1 Proposed Order)(Wilks, David) Modified on 5/23/2025 (nms). (Entered: 05/23/2025)	05/23/2025
71	[SEALED] Exhibits 1-2 to 70 Unopposed Motion for Leave to File Second Amended Complaint, by Genzyme Corporation. (Attachments: # 1 Exhibit 2, # 2 Certificate of Service)(Wilks, David) Modified on 5/23/2025 (nms). Modified on 5/27/2025 (nms). (Entered: 05/23/2025)	05/23/2025
72	NOTICE of Withdrawal of Pro Hac Vice Counsel Jonathan Loeb by Genzyme Corporation (Vavala, Donald) (Entered: 05/27/2025)	05/27/2025
73	ORDER Granting 70 Unopposed Motion for Leave to File Second Amended Complaint. Signed by Judge Richard G. Andrews on 5/27/2025. (nms) (Entered: 05/27/2025)	05/27/2025
74	[SEALED] Second Amended Complaint against Sarepta Therapeutics Three, LLC, Sarepta Therapeutics, Inc. - filed by Genzyme Corporation. (Attachments: # 1 Exhibits A-F, # 2 Exhibits G-L, # 3 Exhibits M-R, # 4 Exhibits S-X, # 5 Certificate of Service)(Wilks, David) Modified on 5/27/2025 (nms). (Entered: 05/27/2025)	05/27/2025
	CORRECTING ENTRY: The Second Amended Complaint filed at D.I. 74 has been removed from the docket. Counsel will refile the amended complaint along with any exhibits referred to therein. (nms) (Entered: 05/27/2025)	05/27/2025
75	Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 9,051,542; 7,704,721; 12,031,894; 12,013,326 ; 11,698,377; 12,123,880 ; 12,298,313 . (Vavala, Donald) (Entered: 05/28/2025)	05/28/2025
	DEFICIENCY NOTICE by the Court issued to Plaintiff re 74 Second Amended Complaint. It is noted that additional patents may have been added to this case, please complete the REPORT TO COMMISSIONER OF PATENTS & TRADEMARKS and docket an additional entry using the PATENT/TRADEMARK REPORT event in the OTHER DOCUMENT list. (nms) (Entered: 05/28/2025)	05/28/2025
76	REDACTED VERSION of 74 Second Amended Complaint, by Genzyme Corporation. (Attachments: # 1 Exhibits A-F, # 2 Exhibits G-L, # 3 Exhibits M-R, # 4 Exhibits S-X)(Vavala, Donald) Modified on 5/29/2025 (nms). (Entered: 05/29/2025)	05/29/2025
77	Joint Stipulation to Amend Scheduling Order, by Sarepta Therapeutics Three, LLC, Sarepta Therapeutics, Inc.. (Fahnestock, Derek) Modified on 5/29/2025 (nms). (Entered: 05/29/2025)	05/29/2025
78	SO ORDERED Granting 77 Joint Stipulation to Amend Scheduling Order (*Reset Deadlines/Hearings: Fact Discovery completed by 6/30/2026; Joint Claim Construction Brief due by 3/16/2026; a Markman Hearing is set for 4/8/2026, at 9:00 AM in Courtroom 6A; Dispositive/Daubert Motions due by 1/8/2027, Answering Dispositive/Daubert Briefs due by 2/5/2027; Reply Dispositive/Daubert Briefs due by 3/5/2027; the 5-day Jury Trial is now set to start 6/14/2027, at 9:30 AM in Courtroom 6A; ; a Pretrial Conference is set for 6/4/2027, at 9:30 AM in Courtroom 6A (see Order for further details). Signed by Judge Richard G. Andrews on 5/29/2025. (nms) (Entered: 05/29/2025)	05/29/2025
	DEFICIENCY NOTICE by the Court issued to Plaintiff re 76 Redacted Document. Upon review it was determined this filing was not a complete version of what was filed at D.I. 74 . The redaction reflects the sealed filing was 710 pages in length, but the sealed filing at D.I. 74 was 738 pages in length. Plaintiff is requested to file a revised redacted version no later than three (3) days from the date of this notice. (nms) (Entered: 05/30/2025)	05/30/2025
79	STIPULATION and Proposed Order to Extend Time to Respond to Deficiency Notice - filed by Sarepta Therapeutics Three, LLC, Sarepta Therapeutics, Inc.. (Dellinger, Megan) Modified on 6/3/2025 (nms). (Entered: 06/02/2025)	06/02/2025
80	REDACTED VERSION of 71 Exhibit to a Document by Genzyme Corporation. (Attachments: # 1 Exhibit 2)(Vavala, Donald) (Entered: 06/03/2025)	06/03/2025
	SO ORDERED, re 79 STIPULATION and Proposed Order to Extend Time to Respond to Deficiency Notice by 6/4/2025. Signed by Judge Richard G. Andrews on 6/3/2025. (nms) (Entered: 06/03/2025)	06/03/2025
	REDACTION NOTICE: In accordance with section G of the Administrative Procedures Governing Filing and Service by Electronic Means, redacted versions of sealed documents shall be filed electronically within 7 days of the filing of the sealed document. The records of this case do not reflect the filing of a redacted version of DI # 71 . (nms) (Entered: 06/03/2025)	06/03/2025
81	REDACTED VERSION of 74 Second Amended Complaint, by Genzyme Corporation. (Attachments: # 1 Exhibits A-F, # 2 Exhibits G-L, # 3 Exhibits M-R, # 4 Exhibits S-X)(Vavala, Donald) Modified on 6/4/2025 (nms). (Entered: 06/04/2025)	06/04/2025
	CORRECTING ENTRY: The document filed as a "Second Amended Complaint" at D.I. 81 has been removed from the docket. Upon review it was determined this filing was a redacted version of a sealed filing. Counsel is to resubmit the redaction using the "Redacted Document" filing code and link the filing to the sealed version. (nms) (Entered: 06/04/2025)	06/04/2025
82	STIPULATION and Proposed Order to Extend Time to Respond to Second Amended Complaint - filed by Sarepta Therapeutics Three, LLC, Sarepta Therapeutics, Inc.. (Fahnestock, Derek) Modified on 6/9/2025 (nms). (Entered: 06/09/2025)	06/09/2025

#	Docket Text	Date Filed
	SO ORDERED, re 82 STIPULATION and Proposed Order to Extend Time to Respond to Second Amended Complaint (*Reset Answer Deadlines: Sarepta Therapeutics Three, LLC answer due 6/17/2025; Sarepta Therapeutics, Inc. answer due 6/17/2025). Signed by Judge Richard G. Andrews on 6/9/2025. (nms) (Entered: 06/09/2025)	06/09/2025
83	NOTICE OF SERVICE of (1) Sarepta Therapeutics, Inc. and Sarepta Therapeutics Three, LLC's Amended Second Set of Requests for Production of Documents and Things to Plaintiff Genzyme Corporation (Nos. 11-82) and (2) Sarepta Therapeutics, Inc. and Sarepta Therapeutics Three, LLC's Amended First Set of Interrogatories to Plaintiff Genzyme Corporation (Nos. 1-10) - filed by Sarepta Therapeutics Three, LLC, Sarepta Therapeutics, Inc..(Fahnestock, Derek) (Entered: 06/10/2025)	06/10/2025
84	ANSWER to 74 Amended Complaint with Jury Demand, by Sarepta Therapeutics Three, LLC, Sarepta Therapeutics, Inc.. (Fahnestock, Derek) Modified on 6/17/2025 (nms). (Entered: 06/17/2025)	06/17/2025
85	NOTICE OF SERVICE of Sarepta Therapeutics, Inc. and Sarepta Therapeutics Three, LLC's Amended Initial Disclosures Pursuant to Fed. R. CIV. P. 26(a)(1) - filed by Sarepta Therapeutics Three, LLC, Sarepta Therapeutics, Inc..(Fahnestock, Derek) (Entered: 06/25/2025)	06/25/2025
86	NOTICE OF SERVICE of Plaintiffs Rule 26(a)(1) Amended Initial Disclosures filed by Genzyme Corporation.(Wilks, David) (Entered: 06/25/2025)	06/25/2025
87	NOTICE OF SERVICE of Sarepta Therapeutics, Inc. and Sarepta Therapeutics Three, LLC's Third Set of Requests for Production of Documents and Things to Plaintiff Genzyme Corporation (Nos. 83-89) - filed by Sarepta Therapeutics Three, LLC, Sarepta Therapeutics, Inc..(Fahnestock, Derek) (Entered: 06/26/2025)	06/26/2025
88	NOTICE OF SERVICE of Sarepta Therapeutics, Inc. and Sarepta Therapeutics Three, LLC's Amended Disclosures Pursuant to Paragraph 3 of the Default Standard for Discovery, Including Discovery of Electronically Stored Information - filed by Sarepta Therapeutics Three, LLC, Sarepta Therapeutics, Inc..(Fahnestock, Derek) (Entered: 07/16/2025)	07/16/2025
89	NOTICE OF SERVICE of 1) Plaintiffs Amended Paragraph 3 Disclosures under the Default Standard for Discovery; and 2) Plaintiffs Amended Disclosures under Paragraph 4(a) of the Default Standard for Discovery filed by Genzyme Corporation.(Wilks, David) (Entered: 07/16/2025)	07/16/2025
90	NOTICE OF SERVICE of 1) Genzyme Corporations Responses to Sarepta Therapeutics, Inc. and Sarepta Therapeutics Three LLCs Second Set of Requests for Production of Documents and Things (Nos. 11-82); and 2) Genzyme Corporations Objections and Responses to Sarepta Therapeutics, Inc. and Sarepta Therapeutics Three, LLCs Amended First Set of Interrogatories (Nos. 1-10) filed by Genzyme Corporation.(Vavala, Donald) (Entered: 07/24/2025)	07/24/2025
91	NOTICE OF SERVICE of Genzyme Corporations Responses to Sarepta Therapeutics, Inc. and Sarepta Therapeutics Three LLCs Third Set of Requests for Production of Documents and Things (Nos. 83-89) filed by Genzyme Corporation.(Vavala, Donald) (Entered: 07/28/2025)	07/28/2025
92	NOTICE OF SERVICE of Plaintiffs Fourth Set of Requests for Production of Documents and Things filed by Genzyme Corporation. (Wilks, David) (Entered: 08/06/2025)	08/06/2025
93	NOTICE OF SERVICE of Sarepta Therapeutics, Inc. and Sarepta Therapeutics Three, LLC's First Supplemental Objections and Responses to Plaintiff Genzyme Corporation's First Set of Interrogatories (Nos. 2, 6) - filed by Sarepta Therapeutics Three, LLC, Sarepta Therapeutics, Inc..(Fahnestock, Derek) (Entered: 08/15/2025)	08/15/2025
94	Amended Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Sarepta Therapeutics, Inc. for Sarepta Therapeutics Three, LLC; Other Affiliate BlackRock, Inc. for Sarepta Therapeutics, Inc. filed by Sarepta Therapeutics Three, LLC, Sarepta Therapeutics, Inc.. (Fahnestock, Derek) (Entered: 08/20/2025)	08/20/2025
95	NOTICE OF SERVICE of Plaintiff Genzyme Corporations Supplemental Initial Claim Charts on Infringement Pursuant to Paragraph 4(c) of the Default Standard for Discovery filed by Genzyme Corporation.(Vavala, Donald) (Entered: 09/15/2025)	09/15/2025
96	NOTICE OF SERVICE of Sarepta Therapeutics, Inc. and Sarepta Therapeutics Three, LLC's Objections and Responses to Plaintiff Genzyme Corporation's Fourth Set of Requests for Production of Documents and Things (Nos. 158-185) - filed by Sarepta Therapeutics Three, LLC, Sarepta Therapeutics, Inc..(Fahnestock, Derek) (Entered: 09/19/2025)	09/19/2025
97	STIPULATION and [Proposed] Order to Extend Certain Deadlines - by Sarepta Therapeutics Three, LLC, Sarepta Therapeutics, Inc.. (Fahnestock, Derek) (Entered: 10/10/2025)	10/10/2025
	SO ORDERED, re 97 Stipulation and Proposed Order to Extend Certain Deadlines. Signed by Judge Richard G. Andrews on 10/10/2025. (nms) (Entered: 10/10/2025)	10/10/2025
98	NOTICE OF SERVICE of Sarepta Therapeutics, Inc. and Sarepta Therapeutics Three, LLC's Supplemental Initial Invalidity Contentions - filed by Sarepta Therapeutics Three, LLC, Sarepta Therapeutics, Inc..(Fahnestock, Derek) (Entered: 10/22/2025)	10/22/2025
99	NOTICE OF SERVICE of Plaintiffs Fifth Set of Requests for Production of Documents and Things filed by Genzyme Corporation. (Vavala, Donald) (Entered: 10/24/2025)	10/24/2025
100	NOTICE of Service of Subpoenas, by Genzyme Corporation. (Wilks, David) Modified on 11/5/2025 (nms). (Entered: 11/05/2025)	11/05/2025

#	Docket Text	Date Filed
	CORRECTING ENTRY: The Notice of Service of Subpoenas filed at D.I. 100 on 11/5/2025, has been removed from the docket per the filer's request. Errors were identified in the filing. (nms) (Entered: 11/05/2025)	11/05/2025
101	STIPULATION and Proposed Order to Extend Certain Deadline - filed by Genzyme Corporation. (Wilks, David) Modified on 11/7/2025 (nms). (Entered: 11/07/2025)	11/07/2025
102	NOTICE OF SERVICE of Sarepta Therapeutics, Inc. and Sarepta Therapeutics Three, LLC's Fourth Set of Requests for Production of Documents and Things to Plaintiff Genzyme Corporation (Nos. 90-101) - filed by Sarepta Therapeutics Three, LLC, Sarepta Therapeutics, Inc..(Fahnestock, Derek) (Entered: 11/07/2025)	11/07/2025
	SO ORDERED, re 101 STIPULATION and Proposed Order to Extend Certain Deadline. Joint Claim Construction Chart to be filed by 11/24/2025. Ordered by Judge Richard G. Andrews on 11/7/2025. (nms) (Entered: 11/07/2025)	11/07/2025
103	NOTICE of Service of Plaintiff's Claim Construction Disclosure by Genzyme Corporation (Wilks, David) (Entered: 11/12/2025)	11/12/2025
104	NOTICE OF SERVICE of Defendants' Claim Terms and Proposed Constructions filed by Sarepta Therapeutics Three, LLC, Sarepta Therapeutics, Inc..(Dellinger, Megan) (Entered: 11/13/2025)	11/13/2025
105	STIPULATION and Proposed Order to Extend Certain Deadlines - filed by Genzyme Corporation. (Wilks, David) Modified on 11/24/2025 (nms). (Entered: 11/24/2025)	11/24/2025
106	NOTICE OF SERVICE of Sarepta Therapeutics, Inc. and Sarepta Therapeutics Three, LLC's Objections and Responses to Plaintiff Genzyme Corporation's Fifth Set of Requests for Production of Documents and Things (Nos. 186-209) - filed by Sarepta Therapeutics Three, LLC, Sarepta Therapeutics, Inc..(Fahnestock, Derek) (Entered: 11/24/2025)	11/24/2025
	SO ORDERED, re 105 STIPULATION and Proposed Order to Extend Certain Deadlines. Ordered by Judge Richard G. Andrews on 11/24/2025. (nms) (Entered: 11/24/2025)	11/24/2025
107	STIPULATION and Proposed Order to Extend Certain Deadlines - filed by Sarepta Therapeutics Three, LLC, Sarepta Therapeutics, Inc.. (Dellinger, Megan) Modified on 11/26/2025 (nms). (Entered: 11/26/2025)	11/26/2025
	SO ORDERED, re 107 STIPULATION and Proposed Order to Extend Certain Deadlines. Ordered by Judge Richard G. Andrews on 11/26/2025. (nms) (Entered: 11/26/2025)	11/26/2025
108	JOINT Claim Construction Chart, by Genzyme Corporation. (Attachments: # 1 Exhibit A, # 2 Exhibit AA, # 3 Exhibit AB, # 4 Exhibit AC, # 5 Exhibit B, # 6 Exhibit C, # 7 Exhibit D, # 8 Exhibit E, # 9 Exhibit F, # 10 Exhibit G, # 11 Exhibit H, # 12 Exhibit I, # 13 Exhibit J, # 14 Exhibit K, # 15 Exhibit L, # 16 Exhibit M, # 17 Exhibit N, # 18 Exhibit O, # 19 Exhibit P, # 20 Exhibit Q, # 21 Exhibit R, # 22 Exhibit S, # 23 Exhibit T, # 24 Exhibit U, # 25 Exhibit V, # 26 Exhibit W, # 27 Exhibit X, # 28 Exhibit Y, # 29 Exhibit Z)(Wilks, David) Modified on 12/2/2025 (nms). (Entered: 12/01/2025)	12/01/2025
109	NOTICE OF SERVICE of Genzyme Corporations Objections and Responses to Sarepta Therapeutics, Inc. and Sarepta Therapeutics Three LLCs Fourth Set of Requests for Production of Documents and Things filed by Genzyme Corporation.(Wilks, David) (Entered: 12/08/2025)	12/08/2025
110	NOTICE of Service of Plaintiffs Sixth Set of Requests for Production of Documents and Things, by Genzyme Corporation. (Wilks, David) Modified on 12/18/2025 (nms). (Entered: 12/17/2025)	12/17/2025
111	NOTICE of Service for Plaintiff's Opening Claim Construction Brief, by Genzyme Corporation. (Vavala, Donald) Modified on 12/22/2025 (nms). (Entered: 12/22/2025)	12/22/2025
112	NOTICE OF SERVICE of Sarepta Therapeutics, Inc. and Sarepta Therapeutics Three, LLC's Objections and Responses to Plaintiff Genzyme Corporation's Sixth Set of Requests for Production of Documents and Things (No. 210) - filed by Sarepta Therapeutics Three, LLC, Sarepta Therapeutics, Inc..(Fahnestock, Derek) (Entered: 01/16/2026)	01/16/2026
113	NOTICE OF SERVICE of (1) Defendants' Answering Claim Construction Brief and (2) Declaration of Mansoor Amiji, R.Ph., Ph.D. filed by Sarepta Therapeutics Three, LLC, Sarepta Therapeutics, Inc..(Fahnestock, Derek) (Entered: 01/27/2026)	01/27/2026
114	MOTION for Pro Hac Vice Appearance of Attorney Alexandra Kim and Yihan Liu - filed by Sarepta Therapeutics Three, LLC, Sarepta Therapeutics, Inc.. (Fahnestock, Derek) (Entered: 01/28/2026)	01/28/2026
115	Pro Hac Vice Fee - Credit Card Payment received for Alexandra Kim and Yihan Liu. (re 114 MOTION for Pro Hac Vice Appearance of Attorney Alexandra Kim and Yihan Liu)(Payment of \$ 100, receipt number ADEDC-4887457).(Fahnestock, Derek) (Entered: 01/28/2026)	01/28/2026
116	MOTION for Pro Hac Vice Appearance of Attorney Shyam Shanker - filed by Genzyme Corporation. (Vavala, Donald) (Entered: 01/28/2026)	01/28/2026
117	Pro Hac Vice Fee - Credit Card Payment received for Shyam Esquire. (re 116 MOTION for Pro Hac Vice Appearance of Attorney Shyam Shanker)(Payment of \$ 50, receipt number ADEDC-4887697).(Vavala, Donald) (Entered: 01/28/2026)	01/28/2026
	SO ORDERED, re 114 MOTION for Pro Hac Vice Appearance of Attorney Alexandra Kim and Yihan Liu filed by Sarepta Therapeutics Three, LLC, Sarepta Therapeutics, Inc.. Signed by Judge Richard G. Andrews on 1/28/2026. (aas) (Entered: 01/28/2026)	01/28/2026

#	Docket Text	Date Filed
	SO ORDERED, re 116 MOTION for Pro Hac Vice Appearance of Attorney Shyam Shanker filed by Genzyme Corporation. Signed by Judge Richard G. Andrews on 1/28/2026. (aas) (Entered: 01/28/2026)	01/28/2026
	Pro Hac Vice Attorney Shyam Shanker for Genzyme Corporation added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (slk) (Entered: 01/30/2026)	01/30/2026
	Pro Hac Vice Attorney Yihan Liu & Alexandra Kim for Sarepta Therapeutics Three, LLC & Sarepta Therapeutics, Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (slk) (Entered: 01/30/2026)	01/30/2026
118	ORAL ORDER: Due to a scheduling conflict the Markman Hearing scheduled for 4/8/2026, is CANCELED. The Markman Hearing is now rescheduled for 4/22/2026, at 9:30 AM in Courtroom 6A. Ordered by Judge Richard G. Andrews on 2/3/2026. (nms) (Entered: 02/03/2026)	02/03/2026
119	MOTION for Pro Hac Vice Appearance of Attorney Judah Bellin - filed by Genzyme Corporation. (Czerwonka, Scott) (Entered: 02/04/2026)	02/04/2026
120	Pro Hac Vice Fee - Credit Card Payment received for Judah Bellin. (re 119 MOTION for Pro Hac Vice Appearance of Attorney Judah Bellin)(Payment of \$ 50, receipt number ADEDC-4892906).(Czerwonka, Scott) (Entered: 02/04/2026)	02/04/2026
	SO ORDERED, re 119 MOTION for Pro Hac Vice Appearance of Attorney Judah Bellin filed by Genzyme Corporation. Signed by Judge Richard G. Andrews on 2/4/2026. (aas) (Entered: 02/04/2026)	02/04/2026
121	ORAL ORDER: The parties have advised that disputes have arisen requiring attention. The Court will hold a discovery conference on 2/25/2026, at 2:00 PM in Courtroom 6A. In preparation for this conference the parties shall follow the Discovery Matters and Disputes procedure as set forth in the Scheduling Order. Ordered by Judge Richard G. Andrews on 2/5/2026. (aas) (Entered: 02/05/2026)	02/05/2026
122	NOTICE of Plaintiff's Notice of Deposition of Dr. Mansoor Amiji, by Genzyme Corporation. (Wilks, David) Modified on 2/5/2026 (nms). (Entered: 02/05/2026)	02/05/2026
	Pro Hac Vice Attorney Judah Bellin for Genzyme Corporation added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (slk) (Entered: 02/05/2026)	02/05/2026
123	NOTICE OF SERVICE of (1) Sarepta Therapeutics, Inc. and Sarepta Therapeutics Three, LLC's Second Amended Disclosures Pursuant to Paragraph 3 of the Default Standard for Discovery, Including Discovery of Electronically Stored Information, (2) Sarepta Therapeutics, Inc. and Sarepta Therapeutics Three, LLC's Second Amended Initial Disclosures Pursuant to Fed. R. Civ. P. 26(a)(1) and (3) Sarepta Therapeutics, Inc. and Sarepta Therapeutics Three, LLC's First Supplemental Objections and Responses to Plaintiff Genzyme Corporations First Set of Interrogatories (No. 1) - filed by Sarepta Therapeutics Three, LLC, Sarepta Therapeutics, Inc..(Fahnestock, Derek) (Entered: 02/06/2026)	02/06/2026
124	NOTICE of Genzyme Corporations Supplemental Objections and Responses to Sarepta Therapeutics, Inc. and Sarepta Therapeutics Three LLCs Amended First Set of Interrogatories (No. 9). was served by Genzyme Corporation (Wilks, David) (Entered: 02/09/2026)	02/09/2026
125	[SEALED] Letter to the Honorable Richard G. Andrews, from David E. Wilks, regarding discovery dispute. (Attachments: # 1 Exhibit 1, # 2 Exhibits 2-10)(Wilks, David) Modified on 2/13/2026 (nms). (Main Document 125 replaced on 2/17/2026) (nms). (Entered: 02/13/2026)	02/13/2026
126	NOTICE of Service of Plaintiff Genzyme Corporations Letter to the Honorable Richard G. Andrews Regarding Privilege Dispute by Genzyme Corporation re 125 Letter (Wilks, David) (Entered: 02/16/2026)	02/16/2026
126	NOTICE of Plaintiff Genzyme Corporations Letter to the Honorable Richard G. Andrews Regarding Discovery Dispute by Genzyme Corporation re 125 Letter (Wilks, David) (Entered: 02/17/2026)	02/17/2026
127	NOTICE OF SERVICE of (1) Sarepta Therapeutics, Inc. and Sarepta Therapeutics Three, LLC's Fourth Set of Requests for Production of Documents and Things to Plaintiff Genzyme Corporation (Nos. 102-104) and (2) Sarepta Therapeutics, Inc. and Sarepta Therapeutics Three, LLC's Second Set of Interrogatories to Plaintiff Genzyme Corporation (No. 11) - filed by Sarepta Therapeutics Three, LLC, Sarepta Therapeutics, Inc..(Fahnestock, Derek) (Entered: 02/17/2026)	02/17/2026
128	NOTICE of Service of (1) Plaintiffs Reply Claim Construction Brief (2) Declaration of Martyn C. Davies, Ph.D by Genzyme Corporation (Wilks, David) (Entered: 02/17/2026)	02/17/2026
	CORRECTING ENTRY: The Notice of Service filed at D.I. 126 on 2/16/2026, has been removed from the docket per the filer's request. A corrected Notice of Service will be refiled. (nms) (Entered: 02/17/2026)	02/17/2026
	CORRECTING ENTRY: The pdf for the letter filed at D.I. 125 has been replaced with a corrected version. The title on the cover page has been amended. (nms) (Entered: 02/17/2026)	02/17/2026
129	NOTICE to Take Deposition of Martyn C. Davies, Ph.D. on February 27, 2026 filed by Sarepta Therapeutics Three, LLC, Sarepta Therapeutics, Inc..(Fahnestock, Derek) (Entered: 02/18/2026)	02/18/2026

#	Docket Text	Date Filed
130	[SEALED] Letter to The Honorable Richard G. Andrews from Derek J. Fahnestock regarding Discovery Dispute. (Attachments: # 1 Exhibits A -B, # 2 Proposed Order)(Fahnestock, Derek) (Entered: 02/18/2026)	02/18/2026